Aeterna Zentaris
AEZS
$8.52
Share price
-0.35%
Change (1 day)
187.84%
Change (1 year)
Categories
Aeterna Zentaris (AEZS) - P/B ratio
P/B ratio as of May 2024 : 0.5684
According to Aeterna Zentaris's latest financial reports the company has a price-to-book ratio of 0.5684.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Aeterna Zentaris - P/B ratio (from 2001 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 0.4966 | 14.92% |
| 2022-12-31 | 0.4321 | -47.15% |
| 2021-12-31 | 0.8176 | -59.31% |
| 2020-12-31 | 2.01 | -127.17% |
| 2019-12-31 | -7.40 | -128.78% |
| 2018-12-31 | 25.7 | -283.45% |
| 2017-12-31 | -14.0 | -307.71% |
| 2016-12-31 | 6.74 | 229.16% |
| 2015-12-31 | 2.05 | -23.78% |
| 2014-12-31 | 2.69 | -26.67% |
| 2013-12-31 | 3.67 | -140.67% |
| 2012-12-31 | -9.01 | -74.12% |
| 2011-12-31 | -34.8 | -401.89% |
| 2010-12-31 | 11.5 | 107.79% |
| 2009-12-31 | 5.55 | 357.41% |
| 2008-12-31 | 1.21 | 31.26% |
| 2007-12-31 | 0.9246 | -23.2% |
| 2006-12-31 | 1.20 | -51.34% |
| 2005-12-31 | 2.47 | 11.63% |
| 2004-12-31 | 2.22 | 74.14% |
| 2003-12-31 | 1.27 | -28.09% |
| 2002-12-31 | 1.77 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 5.29 | 830.35% | 🇨🇭 Switzerland |
 Sanofi SNY | 1.49 | 162.81% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | 5.39 | 848.87% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | 7.89 | 1,287.47% | 🇺🇸 USA |
 Halozyme Therapeutics HALO | 67.9 | 11,845.03% | 🇺🇸 USA |